Search Results

You are looking at 131 - 140 of 203 items for :

  • "lymph node dissection" x
  • Refine by Access: All x
Clear All
Full access

Neal Andruska, Benjamin W. Fischer-Valuck, Ruben Carmona, Temitope Agabalogun, Randall J. Brenneman, Hiram A. Gay, Jeff M. Michalski, and Brian C. Baumann

cancer, including radical prostatectomy with or without pelvic lymph node dissection, external-beam radiation therapy (EBRT) with 4 to 6 months of androgen deprivation therapy (ADT), or combination EBRT with a brachytherapy (BT) boost with or without ADT

Full access

Michelle T. Ashworth and Adil Daud

chest, abdomen, and pelvis identified no other lesions, and results of a complete right inguinal lymph node dissection were negative. The patient was treated with adjuvant radiotherapy (XRT), complicated by a nonhealing ulcer for 1 year and persistent

Full access

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

omental caking. CA-125 serum tumor marker at time of presentation was elevated at 1,155 kU/L (normal range, <35 kU/L). The patient underwent primary surgery with radical hysterectomy, bilateral salpingo-oophorectomy, lymph node dissection, and removal of

Full access

Saranya Chumsri, Ethan S. Sokol, Aixa E. Soyano-Muller, Ricardo D. Parrondo, Gina A. Reynolds, Aziza Nassar, and E. Aubrey Thompson

subsequently underwent right modified radical mastectomy with axillary lymph node dissection. Pathology results showed multifocal residual disease measuring up to 16.5 cm, with >10 additional satellite tumors and skin involvement. Among resected axillary lymph

Full access

Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell

with retroperitoneal lymph node dissection only? Which patients with stage II and III disease will need to undergo resection of residual masses after chemotherapy?” he continued. Dr. Gilligan explained that the 8th edition has made some changes, but

Full access

James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, and Patrick C. Walsh

decision-making for men contemplating active surveillance, 12 radical prostatectomy, 13 – 15 neurovascular bundle preservation, 16 – 18 or omission of pelvic lymph node dissection (PLND) during radical prostatectomy, 19 brachytherapy, 13 , 20 , 21 or

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars

pregnant during breast cancer treatment (see page 160). Locoregional Treatment Several randomized trials document that mastectomy with axillary lymph node dissection is equivalent to breast-conserving therapy with lumpectomy, axillary dissection

Full access

Lyndsay J. Willmott, Daniele A. Sumner, and Bradley J. Monk

treatment protocol is surgical resection, typically with radical hysterectomy and pelvic lymph node dissection. Cure rates are good in this instance. However, more advanced disease is a greater challenge to treat effectively. The American Cancer Society

Full access

Andrea Maurichi, Rosalba Miceli, Roberto Patuzzo, Francesco Barretta, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Umberto Cortinovis, Elena Tolomio, Milena Sant, Gianpiero Castelli, Leonardo Zichichi, Giovanni Pellacani, Ignazio Stanganelli, Marco Simonacci, Ausilia Manganoni, Corrado Del Forno, Gioachino Caresana, Catherine Harwood, Daniele Bergamaschi, Konstantinos Lasithiotakis, Dorothy Bennett, Vittoria Espeli, Cristina Mangas, Sandra Leoni Parvex, Barbara Valeri, Mara Cossa, Marta Barisella, Alessandro Pellegrinelli, Claudia Miranda, Andrea Anichini, Roberta Mortarini, Odysseas Zoras, and Mario Santinami

completion lymph node dissection (CLND) as additional therapy. Statistical Methods Clinicopathologic characteristics were recorded according to SNB (performed vs not performed) for the whole series of patients, according to SN status (positive vs negative) in

Full access

David J. Worhunsky, Yifei Ma, Yulia Zak, George A. Poultsides, Jeffrey A. Norton, Kim F. Rhoads, and Brendan C. Visser

Although multiple quality indicators have been studied for the management of gastric cancer, notably surgical technique and the extent of lymph node dissection, 12 – 14 limited data exist regarding implementation and effectiveness of clinical guidelines